Metoprolol Safety in First Trimester
Metoprolol can be used during the first trimester of pregnancy when clinically necessary, though it should be used with caution as it is FDA Pregnancy Category C with limited human data. 1
Guideline Recommendations
The European Society of Cardiology (ESC) guidelines explicitly state that metoprolol is recommended for hypertension management during pregnancy 1. Importantly, the guidelines note that women with pre-existing hypertension may continue their current medication during pregnancy, with the critical exception of ACE inhibitors, ARBs, and direct renin inhibitors which are strictly contraindicated due to severe fetotoxicity 1.
Key Distinction for First Trimester
The guidelines make an important temporal distinction: if ACE inhibitors or ARBs are taken inadvertently during the first trimester only, switching to another medication (such as metoprolol) and close monitoring including fetal ultrasound are advisable and usually sufficient 1. This suggests the first trimester carries less risk than later trimesters for certain medications, though metoprolol itself does not have this same restriction pattern.
FDA Drug Label Information
The FDA classifies metoprolol as Pregnancy Category C, meaning:
- Animal studies showed embryotoxicity/fetotoxicity at high doses (50 mg/kg in rats, 25 mg/kg in rabbits), including increased preimplantation loss, decreased viable fetuses, decreased neonatal survival, and growth delays 2
- No teratogenic potential was demonstrated in reproduction toxicity studies in mice, rats, and rabbits 2
- No adequate and well-controlled studies exist in pregnant women 2
- The risk to the fetus/mother is unknown 2
- The label states it "should be used during pregnancy only if clearly needed" 2
Critical Caveat
Upon confirming pregnancy, women should immediately inform their doctor 2. This emphasizes the need for early pregnancy monitoring when metoprolol is used.
Clinical Evidence on Timing
Research evidence provides important context about when during pregnancy metoprolol poses the greatest concerns:
- A 2020 cohort study found that long-term exposure during the second and third trimesters was associated with increased risk of small-for-gestational-age infants (24.1% vs 9.9% in non-hypertensive controls) 3
- The study noted that serious neonatal symptoms are rare and metoprolol/bisoprolol are "well tolerated treatment options" 3
- Older pharmacokinetic studies from the 1980s focused on late pregnancy exposure, not first trimester 4, 5
This evidence suggests the primary concerns with metoprolol are related to second and third trimester exposure affecting fetal growth, not first trimester teratogenicity.
Practical Clinical Approach
When to Use Metoprolol in First Trimester:
- Pre-existing hypertension requiring beta-blocker therapy - Continue if already on metoprolol when pregnancy is discovered
- Cardiac arrhythmias requiring rate control - Metoprolol is an acceptable option 6
- When preferred agents (methyldopa, labetalol) are contraindicated or ineffective
What to Monitor:
- Immediate notification to physician upon pregnancy confirmation 2
- Fetal ultrasound monitoring for growth assessment 1
- Consider switching to methyldopa or labetalol if clinically appropriate, as these have longer safety records 1
Common Pitfall to Avoid:
Do not confuse metoprolol with ACE inhibitors/ARBs. While ACE inhibitors are absolutely contraindicated throughout pregnancy with severe fetotoxicity, metoprolol does not carry this same level of contraindication. The guidelines explicitly recommend metoprolol as an option 1, whereas ACE inhibitors are strictly forbidden.
Bottom Line
Metoprolol is not contraindicated in the first trimester and can be used when clinically indicated for maternal cardiovascular conditions. The lack of teratogenic effects in animal studies 2, combined with explicit guideline recommendations for its use in pregnancy 1, support its safety profile. However, given the FDA Category C designation and limited human data, it should be reserved for situations where the maternal benefit justifies the potential fetal risk, with appropriate monitoring throughout pregnancy.